Found: 33
Select item for more details and to access through your institution.
Excess Weight Gain With Integrase Inhibitors and Tenofovir Alafenamide: What Is the Mechanism and Does It Matter?
- Published in:
- Open Forum Infectious Diseases, 2021, v. 8, n. 12, p. 1, doi. 10.1093/ofid/ofab542
- By:
- Publication type:
- Article
Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate.
- Published in:
- Open Forum Infectious Diseases, 2020, v. 7, n. 1, p. N.PAG, doi. 10.1093/ofid/ofz472
- By:
- Publication type:
- Article
887. High Rates of Virologic Suppression Achieved in HIV-1–Infected Adults Rapidly Starting Antiretroviral Therapy (ART) with the Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) 800/150/200/10 mg Regardless of Baseline Disease Characteristics: Week 48 Subgroup Analyses From the Phase 3 DIAMOND Trial
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S21, doi. 10.1093/ofid/ofz359.046
- By:
- Publication type:
- Article
Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, n. 4, p. N.PAG, doi. 10.1093/ofid/ofz099
- By:
- Publication type:
- Article
A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2.
- Published in:
- Infectious Diseases & Therapy, 2021, v. 10, n. 4, p. 1933, doi. 10.1007/s40121-021-00515-6
- By:
- Publication type:
- Article
Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
- Published in:
- Frontiers in Immunology, 2021, v. 12, p. 1, doi. 10.3389/fimmu.2021.790469
- By:
- Publication type:
- Article
Spectrum of infection and risk factors for human monkeypox, United States, 2003.
- Published in:
- 2007
- By:
- Publication type:
- journal article
Myocarditis Outbreak among Adults, Illinois, 2003.
- Published in:
- Emerging Infectious Diseases, 2005, v. 11, n. 10, p. 1621, doi. 10.3201/eid1110.041152
- By:
- Publication type:
- Article
Association of HIV Infection, Hepatitis C Virus Infection, and Metabolic Factors With Liver Stiffness Measured by Transient Elastography.
- Published in:
- Journal of Infectious Diseases, 2013, v. 208, n. 11, p. 1776, doi. 10.1093/infdis/jit357
- By:
- Publication type:
- Article
Clinical Manifestations of Human Monkeypox Influenced by Route of Infection.
- Published in:
- Journal of Infectious Diseases, 2006, v. 194, n. 6, p. 773, doi. 10.1086/505880
- By:
- Publication type:
- Article
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.
- Published in:
- BMC Infectious Diseases, 2013, v. 13, n. 1, p. 1, doi. 10.1186/1471-2334-13-269
- By:
- Publication type:
- Article
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Two Outbreaks of Occupationally Acquired Histoplasmosis: More than Workers at Risk.
- Published in:
- Environmental Health Perspectives, 2005, v. 113, n. 5, p. 585, doi. 10.1289/ehp.7484
- By:
- Publication type:
- Article
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.
- Published in:
- PLoS ONE, 2020, v. 15, n. 2, p. 1, doi. 10.1371/journal.pone.0228847
- By:
- Publication type:
- Article
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
- Published in:
- PLoS ONE, 2020, v. 15, n. 1, p. 1, doi. 10.1371/journal.pone.0224875
- By:
- Publication type:
- Article
Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load.
- Published in:
- Clinical Infectious Diseases, 2022, v. 75, n. 1, p. e440, doi. 10.1093/cid/ciab912
- By:
- Publication type:
- Article
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study.
- Published in:
- Clinical Infectious Diseases, 2020, v. 71, n. 12, p. 3110, doi. 10.1093/cid/ciz1213
- By:
- Publication type:
- Article
A Novel Score to Predict Esophageal Varices in Patients with Compensated Advanced Chronic Liver Disease.
- Published in:
- Digestive Diseases & Sciences, 2021, v. 66, n. 6, p. 2084, doi. 10.1007/s10620-020-06456-3
- By:
- Publication type:
- Article
Baseline characteristics associated with clinical improvement and mortality in hospitalized patients with severe COVID-19 treated with remdesivir.
- Published in:
- Infection & Chemotherapy, 2020, v. 52, p. S384
- By:
- Publication type:
- Article
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
- Published in:
- JAMA: Journal of the American Medical Association, 2021, v. 325, n. 7, p. 632, doi. 10.1001/jama.2021.0202
- By:
- Publication type:
- Article
Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection.
- Published in:
- Pharmacotherapy, 2016, v. 36, n. 9, p. e148, doi. 10.1002/phar.1803
- By:
- Publication type:
- Article
WHAT INFLUENCES SWITCHING TO DTG/3TC VS B/F/TAF IN CLINICAL PRACTICE?
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 209
- By:
- Publication type:
- Article
COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine.
- Published in:
- PLoS ONE, 2022, v. 17, n. 9, p. 1, doi. 10.1371/journal.pone.0273323
- By:
- Publication type:
- Article
The ATEAM study: Advances in technology to enhance PrEP adherence monitoring (ATEAM) among young men who have sex with men.
- Published in:
- CTS: Clinical & Translational Science, 2022, v. 15, n. 12, p. 2947, doi. 10.1111/cts.13414
- By:
- Publication type:
- Article
Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non‐adherence.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 51, n. 12, p. 1384, doi. 10.1111/apt.15707
- By:
- Publication type:
- Article
Contribution of Liver Fibrosis and Microbial Translocation to Immune Activation in Persons Infected With HIV and/or Hepatitis C Virus.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A matched cross-sectional study of the association between circulating tissue factor activity, immune activation and advanced liver fibrosis in hepatitis C infection.
- Published in:
- BMC Infectious Diseases, 2015, v. 15, n. 1, p. 1, doi. 10.1186/s12879-015-0920-1
- By:
- Publication type:
- Article
Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate.
- Published in:
- 2019
- By:
- Publication type:
- journal article
West Nile Virus in the United States.
- Published in:
- American Family Physician, 2003, v. 68, n. 4, p. 653
- By:
- Publication type:
- Article
Rash as a Prognostic Factor in West Nile Virus Disease.
- Published in:
- 2006
- By:
- Publication type:
- Letter
Clinical Characteristics of Human Monkeypox, and Risk Factors for Severe Disease.
- Published in:
- Clinical Infectious Diseases, 2005, v. 41, n. 12, p. 1742, doi. 10.1086/498115
- By:
- Publication type:
- Article
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
- Published in:
- AIDS Research & Therapy, 2019, v. 16, n. 1, p. N.PAG, doi. 10.1186/s12981-019-0235-1
- By:
- Publication type:
- Article
Early development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitution.
- Published in:
- AIDS Research & Therapy, 2010, v. 7, p. 44, doi. 10.1186/1742-6405-7-44
- By:
- Publication type:
- Article